Douglas A. Dachille
Douglas A. Dachille's purchase track record
How the stock did after each of Douglas A. Dachille's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/3/2025 | PNC | $20K | -15.3% | -2.5% | +5.6% |
| 3/14/2022 | BBIO | $82K | -27.9% | +49.8% | -1.5% |
| 1/4/2022 | BBIO | $164K | -25.7% | -33.8% | -20.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
EQH to Announce Q3 2026 Results; Analysts Examine Fee‑Based Mix and Index Exit. Equitable Holdings has scheduled its third‑quarter 2026 earnings announcement. Recent analysis looks at how a shift toward fee‑based services could affect the company’s earnings mix, and whether the removal of an index and changes in asset‑management turnover might influence its outlook. These factors are being evaluated as the market awaits the upcoming results.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
PNC Reports Q3 Earnings and TD Cowen Cuts Target. PNC Financial Services Group released its Q3 2026 earnings, highlighting strong results while addressing credit questions on its earnings call. Following the report, TD Cowen maintained its rating on the stock but lowered its price target to $240, which sits below the average analyst target of $265.52.
Transaction History
| BBIO | ▲ Buy | Grant | 3,990 | $0 | 6/22/2026 | View on chart |
| EQH | ▲ Buy | Grant | 4,400 | $185K | 5/20/2026 | View on chart |
| BBIO | ▲ Buy | Grant | 6,589 | $0 | 6/20/2025 | View on chart |
| EQH | ▲ Buy | Grant | 3,393 | $0 | 5/21/2025 | View on chart |
| PNC | ▲ Buy | Open Market | 100 | $20K | 2/3/2025 | View on chart |
| BBIO | ▲ Buy | Open Market | 10,000 | $82K | 3/14/2022 | View on chart |
| BBIO | ▲ Buy | Open Market | 5,000 | $80K | 1/5/2022 | View on chart |
| BBIO | ▲ Buy | Open Market | 5,000 | $84K | 1/4/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
BridgeBio Reports Inducement Grants and Phase 3 Encaleret Success
BridgeBio Pharma announced it has received inducement grants under Nasdaq Rule 5635(c)(4) and released new data from its Phase 3 CALIBRATE trial for Encaleret. The study showed a 100% improvement in at least one ADH1 symptom and increased bone turnover compared with standard care. Additional real‑world data for Acoramidis demonstrated lower composite risk versus Tafamidis in ATTR‑CM patients. These results support the company’s therapeutic pipeline and may influence investor perception.
BridgeBio Reports Inducement Grants and Phase 3 Encaleret Success. BridgeBio Pharma announced it has received inducement grants under Nasdaq Rule 5635(c)(4) and released new data from its Phase 3 CALIBRATE trial for Encaleret. The study showed a 100% improvement in at least one ADH1 symptom and increased bone turnover compared with standard care. Additional real‑world data for Acoramidis demonstrated lower composite risk versus Tafamidis in ATTR‑CM patients. These results support the company’s therapeutic pipeline and may influence investor perception.